LSV Asset Management Buys 67,470 Shares of Exelixis, Inc. (NASDAQ:EXEL)

LSV Asset Management raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 0.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 8,169,847 shares of the biotechnology company's stock after acquiring an additional 67,470 shares during the quarter. LSV Asset Management owned approximately 2.86% of Exelixis worth $272,056,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after buying an additional 121,750 shares during the last quarter. Invesco Ltd. raised its position in shares of Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after buying an additional 3,001,204 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock worth $105,208,000 after purchasing an additional 1,613,482 shares during the last quarter. FMR LLC boosted its holdings in shares of Exelixis by 19.7% in the 4th quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after purchasing an additional 485,527 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Exelixis during the 4th quarter valued at $94,867,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. Corporate insiders own 2.85% of the company's stock.

Exelixis Price Performance

EXEL stock traded up $0.39 during midday trading on Tuesday, reaching $36.13. 905,628 shares of the company's stock traded hands, compared to its average volume of 2,169,248. The business has a 50-day moving average price of $36.21 and a two-hundred day moving average price of $34.08. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02. The company has a market capitalization of $10.11 billion, a P/E ratio of 20.41, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. UBS Group raised their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Stephens reiterated an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and raised their price objective for the stock from $36.00 to $40.00 in a report on Friday, December 20th. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. Finally, Royal Bank of Canada upped their price objective on Exelixis from $38.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.